{"transactions":[{"id":758766,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-29T20:04:59.000Z","date":"2026-05-28","kind":"exercise","planned":false,"acquired":false,"shares":16260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":0,"derivative":{"exercise_price":14.7,"expiration_date":"2033-04-12","underlying":"Common Stock","underlying_shares":16260},"source":{"system":"sec-edgar","filing":"0001341896-26-000004","document":"wk-form4_1780085096.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000134189626000004/wk-form4_1780085096.xml","form_type":"4"}},{"id":758765,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-29T20:04:59.000Z","date":"2026-05-28","kind":"exercise","planned":false,"acquired":false,"shares":77181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.43,"expiration_date":"2029-11-19","underlying":"Common Stock","underlying_shares":77181},"source":{"system":"sec-edgar","filing":"0001341896-26-000004","document":"wk-form4_1780085096.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000134189626000004/wk-form4_1780085096.xml","form_type":"4"}},{"id":758764,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-29T20:04:59.000Z","date":"2026-05-28","kind":"exercise","planned":false,"acquired":false,"shares":71492,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.94,"expiration_date":"2032-01-10","underlying":"Common Stock","underlying_shares":71492},"source":{"system":"sec-edgar","filing":"0001341896-26-000004","document":"wk-form4_1780085096.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000134189626000004/wk-form4_1780085096.xml","form_type":"4"}},{"id":758763,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-29T20:04:59.000Z","date":"2026-05-28","kind":"exercise","planned":false,"acquired":false,"shares":31668,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":0,"derivative":{"exercise_price":4.99,"expiration_date":"2032-08-17","underlying":"Common Stock","underlying_shares":31668},"source":{"system":"sec-edgar","filing":"0001341896-26-000004","document":"wk-form4_1780085096.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000134189626000004/wk-form4_1780085096.xml","form_type":"4"}},{"id":758762,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T20:04:59.000Z","date":"2026-05-28","kind":"sale","planned":false,"acquired":false,"shares":210468,"price":33.56,"value":7063306.08,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.04 - $33.85 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":74382,"source":{"system":"sec-edgar","filing":"0001341896-26-000004","document":"wk-form4_1780085096.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000134189626000004/wk-form4_1780085096.xml","form_type":"4"}},{"id":758761,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T20:04:59.000Z","date":"2026-05-28","kind":"sale","planned":false,"acquired":false,"shares":11483,"price":32.64,"value":374805.12,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.04 - $33.035 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":284850,"source":{"system":"sec-edgar","filing":"0001341896-26-000004","document":"wk-form4_1780085096.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000134189626000004/wk-form4_1780085096.xml","form_type":"4"}},{"id":758760,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T20:04:59.000Z","date":"2026-05-28","kind":"exercise","planned":false,"acquired":true,"shares":16260,"price":14.7,"value":239022.0,"ownership":{"direct":true},"balance_after":296333,"source":{"system":"sec-edgar","filing":"0001341896-26-000004","document":"wk-form4_1780085096.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000134189626000004/wk-form4_1780085096.xml","form_type":"4"}},{"id":758759,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T20:04:59.000Z","date":"2026-05-28","kind":"exercise","planned":false,"acquired":true,"shares":77181,"price":8.43,"value":650635.83,"ownership":{"direct":true},"balance_after":280073,"source":{"system":"sec-edgar","filing":"0001341896-26-000004","document":"wk-form4_1780085096.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000134189626000004/wk-form4_1780085096.xml","form_type":"4"}},{"id":758758,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T20:04:59.000Z","date":"2026-05-28","kind":"exercise","planned":false,"acquired":true,"shares":71492,"price":7.94,"value":567646.48,"ownership":{"direct":true},"balance_after":202892,"source":{"system":"sec-edgar","filing":"0001341896-26-000004","document":"wk-form4_1780085096.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000134189626000004/wk-form4_1780085096.xml","form_type":"4"}},{"id":758757,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T20:04:59.000Z","date":"2026-05-28","kind":"exercise","planned":false,"acquired":true,"shares":31668,"price":4.99,"value":158023.32,"ownership":{"direct":true},"balance_after":131400,"source":{"system":"sec-edgar","filing":"0001341896-26-000004","document":"wk-form4_1780085096.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000134189626000004/wk-form4_1780085096.xml","form_type":"4"}},{"id":811524,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-09T20:28:49.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":7061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":7061,"derivative":{"exercise_price":24.61,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":7061},"source":{"system":"sec-edgar","filing":"0001764013-26-000050","document":"wk-form4_1775766526.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000050/wk-form4_1775766526.xml","form_type":"4"}},{"id":811523,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T20:28:49.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":13880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."}],"balance_after":99732,"source":{"system":"sec-edgar","filing":"0001764013-26-000050","document":"wk-form4_1775766526.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000050/wk-form4_1775766526.xml","form_type":"4"}},{"id":981645,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-03T23:14:54.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":2898,"price":23.95,"value":69407.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.73 - $24.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":85852,"source":{"system":"sec-edgar","filing":"0001764013-25-000160","document":"wk-form4_1764803692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000160/wk-form4_1764803692.xml","form_type":"4"}},{"id":981644,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-03T23:14:54.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":19351,"price":23.14,"value":447782.14,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.73 - $23.72 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":88750,"source":{"system":"sec-edgar","filing":"0001764013-25-000160","document":"wk-form4_1764803692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000160/wk-form4_1764803692.xml","form_type":"4"}},{"id":1179757,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-03T20:41:16.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":7600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the options will vest on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":7600,"derivative":{"exercise_price":15.2,"expiration_date":"2035-04-01","underlying":"Common Stock","underlying_shares":7600},"source":{"system":"sec-edgar","filing":"0001764013-25-000043","document":"wk-form4_1743712868.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000043/wk-form4_1743712868.xml","form_type":"4"}},{"id":1179756,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-03T20:41:16.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":16188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."}],"balance_after":108101,"source":{"system":"sec-edgar","filing":"0001764013-25-000043","document":"wk-form4_1743712868.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000043/wk-form4_1743712868.xml","form_type":"4"}},{"id":1212320,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-11T20:18:47.000Z","date":"2025-03-07","kind":"sale","planned":true,"acquired":false,"shares":1384,"price":19.96,"value":27624.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024 in order to satisfy applicable tax\nobligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.91 - $20.00 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":91913,"source":{"system":"sec-edgar","filing":"0001764013-25-000034","document":"wk-form4_1741724319.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000034/wk-form4_1741724319.xml","form_type":"4"}},{"id":1212319,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-11T20:18:47.000Z","date":"2025-03-07","kind":"sale","planned":true,"acquired":false,"shares":6616,"price":19.52,"value":129144.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024 in order to satisfy applicable tax\nobligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.91 - $19.86 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":93297,"source":{"system":"sec-edgar","filing":"0001764013-25-000034","document":"wk-form4_1741724319.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000034/wk-form4_1741724319.xml","form_type":"4"}},{"id":1547845,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-04T20:54:20.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":4690,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the options will vest on April 2, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":4690,"derivative":{"exercise_price":30.78,"expiration_date":"2034-04-02","underlying":"Common Stock","underlying_shares":4690},"source":{"system":"sec-edgar","filing":"0001764013-24-000067","document":"wk-form4_1712264048.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000067/wk-form4_1712264048.xml","form_type":"4"}},{"id":1547844,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T20:54:20.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":11255,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 2, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."}],"balance_after":99913,"source":{"system":"sec-edgar","filing":"0001764013-24-000067","document":"wk-form4_1712264048.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000067/wk-form4_1712264048.xml","form_type":"4"}},{"id":1721893,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-05T21:30:51.000Z","date":"2023-12-01","kind":"sale","planned":true,"acquired":false,"shares":4773,"price":40.46,"value":193115.58,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan adopted on May 24, 2023, in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering shares of common stock and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.24 - $40.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":88658,"source":{"system":"sec-edgar","filing":"0001764013-23-000156","document":"wk-form4_1701811810.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000156/wk-form4_1701811810.xml","form_type":"4"}},{"id":1721892,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-05T21:30:51.000Z","date":"2023-12-01","kind":"sale","planned":true,"acquired":false,"shares":3636,"price":39.81,"value":144749.16,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan adopted on May 24, 2023, in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering shares of common stock and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.22 - $40.19 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":93431,"source":{"system":"sec-edgar","filing":"0001764013-23-000156","document":"wk-form4_1701811810.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000156/wk-form4_1701811810.xml","form_type":"4"}},{"id":1721891,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-05T21:30:51.000Z","date":"2023-12-01","kind":"sale","planned":true,"acquired":false,"shares":3941,"price":38.78,"value":152831.98,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan adopted on May 24, 2023, in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering shares of common stock and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.19 - $39.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":97067,"source":{"system":"sec-edgar","filing":"0001764013-23-000156","document":"wk-form4_1701811810.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000156/wk-form4_1701811810.xml","form_type":"4"}},{"id":1919635,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-04-14T20:33:00.000Z","date":"2023-04-12","kind":"grant","planned":false,"acquired":true,"shares":16260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the options vest one year after the date of grant on April 12, 2024, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":16260,"derivative":{"exercise_price":14.7,"expiration_date":"2033-04-12","underlying":"Common Stock","underlying_shares":16260},"source":{"system":"sec-edgar","filing":"0001764013-23-000045","document":"wf-form4_168150437013871.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000045/wf-form4_168150437013871.xml","form_type":"4"}},{"id":1919634,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-14T20:33:00.000Z","date":"2023-04-12","kind":"grant","planned":false,"acquired":true,"shares":12523,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the number of shares underlying restricted stock units awards (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs vest in their entirety one year after the date of grant on April 12, 2024, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."}],"balance_after":101008,"source":{"system":"sec-edgar","filing":"0001764013-23-000045","document":"wf-form4_168150437013871.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000045/wf-form4_168150437013871.xml","form_type":"4"}},{"id":2178369,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-19T20:48:23.000Z","date":"2022-08-17","kind":"grant","acquired":true,"shares":31668,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the options vest one year after the date of grant on August 17, 2023, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":31668,"derivative":{"exercise_price":4.99,"expiration_date":"2032-08-17","underlying":"Common Stock","underlying_shares":31668},"source":{"system":"sec-edgar","filing":"0001764013-22-000097","document":"wf-form4_166094208760439.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000097/wf-form4_166094208760439.xml","form_type":"4"}},{"id":2178368,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-19T20:48:23.000Z","date":"2022-08-17","kind":"grant","acquired":true,"shares":21059,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the number of shares underlying restricted stock units awards (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs vest in their entirety one year after the date of grant on August 17, 2023, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."}],"balance_after":88485,"source":{"system":"sec-edgar","filing":"0001764013-22-000097","document":"wf-form4_166094208760439.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000097/wf-form4_166094208760439.xml","form_type":"4"}},{"id":2436893,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-12T22:09:17.000Z","date":"2022-01-10","kind":"grant","acquired":true,"shares":71492,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares underlying the options vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date."}],"balance_after":208973,"derivative":{"exercise_price":7.94,"expiration_date":"2032-01-10","underlying":"Common Stock","underlying_shares":71492},"source":{"system":"sec-edgar","filing":"0001764013-22-000021","document":"wf-form4_164202534055827.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000021/wf-form4_164202534055827.xml","form_type":"4"}},{"id":2436892,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-12T22:09:17.000Z","date":"2022-01-10","kind":"grant","acquired":true,"shares":21726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the number of shares underlying restricted stock units awards (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date."}],"balance_after":67426,"source":{"system":"sec-edgar","filing":"0001764013-22-000021","document":"wf-form4_164202534055827.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000021/wf-form4_164202534055827.xml","form_type":"4"}},{"id":2606985,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-11T18:12:40.000Z","date":"2021-08-10","kind":"purchase","acquired":true,"shares":5500,"price":7.9,"value":43450.0,"ownership":{"direct":true},"balance_after":45700,"source":{"system":"sec-edgar","filing":"0001764013-21-000081","document":"wf-form4_162870554557188.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401321000081/wf-form4_162870554557188.xml","form_type":"4"}},{"id":2775012,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-03-23T12:50:15.000Z","date":"2021-03-19","kind":"grant","acquired":true,"shares":23300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the options vest one year after the date of grant on March 19, 2022, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":23300,"derivative":{"exercise_price":17,"expiration_date":"2031-03-19","underlying":"Common Stock","underlying_shares":23300},"source":{"system":"sec-edgar","filing":"0001764013-21-000041","document":"wf-form4_161650380299067.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401321000041/wf-form4_161650380299067.xml","form_type":"4"}},{"id":2775011,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-23T12:50:15.000Z","date":"2021-03-19","kind":"grant","acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares underlying restricted stock unit awards (\"RSUs\") granted to the Reporting Person pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in their entirety one year after the date of grant on March 19, 2022, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."}],"balance_after":40200,"source":{"system":"sec-edgar","filing":"0001764013-21-000041","document":"wf-form4_161650380299067.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401321000041/wf-form4_161650380299067.xml","form_type":"4"}},{"id":3145699,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-18T12:40:17.000Z","date":"2020-05-15","kind":"grant","acquired":true,"shares":37000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest in eight equal quarterly installments measured from May 15, 2020, subject to the Reporting Person providing continuous service to the Issuer as of each such date."}],"balance_after":37000,"derivative":{"exercise_price":19.01,"expiration_date":"2030-05-14","underlying":"Common Stock","underlying_shares":37000},"source":{"system":"sec-edgar","filing":"0001209191-20-029934","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000120919120029934/doc4.xml","form_type":"4"}},{"id":3145698,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-18T12:40:17.000Z","date":"2020-05-15","kind":"grant","acquired":true,"shares":24700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares underlying restricted stock units awards (\"RSUs\") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the number of shares underlying restricted stock units awards (\"RSUs\") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation."}],"balance_after":24700,"source":{"system":"sec-edgar","filing":"0001209191-20-029934","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000120919120029934/doc4.xml","form_type":"4"}},{"id":3334024,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-12-20T21:51:51.000Z","date":"2019-12-18","kind":"grant","acquired":true,"shares":77181,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the share exchange transaction pursuant to which Health Sciences Acquisitions Corporation (\"HSAC\") acquired 100% of the issued and outstanding shares of Immunovant Sciences Ltd., the option to purchase 157,812 shares of Immunovant Sciences Ltd. at exercise price of $4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer (formerly known as HSAC)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests over a period of three years, with 1/3 of the shares underlying the option vesting on each of the first, second and third anniversaries of the vesting commencement date."}],"balance_after":77181,"derivative":{"exercise_price":8.43,"expiration_date":"2029-11-19","underlying":"Common Stock","underlying_shares":77181},"source":{"system":"sec-edgar","filing":"0001209191-19-061588","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000120919119061588/doc4.xml","form_type":"4"}},{"id":4567451,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:28:42.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":17695,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":8.19,"expiration_date":"2025-01-01","underlying":"Common Stock","underlying_shares":17695},"source":{"system":"sec-edgar","filing":"0001209191-16-148105","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148105/doc4.xml","form_type":"4"}},{"id":4567450,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:28:42.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":17778,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":7.91,"expiration_date":"2026-01-12","underlying":"Common Stock","underlying_shares":17778},"source":{"system":"sec-edgar","filing":"0001209191-16-148105","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148105/doc4.xml","form_type":"4"}},{"id":4567449,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:28:42.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":15500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":16.52,"expiration_date":"2025-07-08","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001209191-16-148105","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148105/doc4.xml","form_type":"4"}},{"id":4567448,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:28:42.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":5666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":58.23,"expiration_date":"2024-06-12","underlying":"Common Stock","underlying_shares":5666},"source":{"system":"sec-edgar","filing":"0001209191-16-148105","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148105/doc4.xml","form_type":"4"}},{"id":4567447,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2016-11-03T14:28:42.000Z","date":"2016-11-01","kind":"other","acquired":false,"shares":5,"ownership":{"direct":false,"nature":"Held by children of Reporting Person"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares tendered for an offer price of $28.35 per share in cash (the \"Closing Amount\"), plus one non-transferable contingent value right per share (each, a \"CVR\"), which represents the contractual right to receive one or more payments in cash of up to $49.84 per share in the aggregate, contingent upon the achievement of certain milestones, in each case without any interest thereon and subject to any required tax withholdings , pursuant to the tender offer consummated on November 1, 2016 according to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allegan Holdco US, Inc.(\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-16-148105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148105/doc4.xml","form_type":"4"}},{"id":4567446,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2016-11-03T14:28:42.000Z","date":"2016-11-01","kind":"other","acquired":false,"shares":11,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares tendered for an offer price of $28.35 per share in cash (the \"Closing Amount\"), plus one non-transferable contingent value right per share (each, a \"CVR\"), which represents the contractual right to receive one or more payments in cash of up to $49.84 per share in the aggregate, contingent upon the achievement of certain milestones, in each case without any interest thereon and subject to any required tax withholdings , pursuant to the tender offer consummated on November 1, 2016 according to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allegan Holdco US, Inc.(\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-16-148105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148105/doc4.xml","form_type":"4"}}]}